raxone
chiesi farmaceutici s.p.a - idebenonas - optinė atrofija, paveldima, leber - kiti psychostimulants ir nootropics, psychoanaleptics, - raxone skiriamas regėjimo sutrikimo gydymui paaugliams ir suaugusiems pacientams, kuriems yra leberio paveldima optinė neuropatija (lhon).
xtandi
astellas pharma europe b.v. - enzalutamidas - prostatos navikai - endokrininė terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
amiokordin
krka, d.d., novo mesto - amjodarono hidrochloridas - injekcinis tirpalas - 200 mg; 50 mg/ml - amiodarone
asentra
krka, d.d., novo mesto - sertralinas - plėvele dengtos tabletės - 100 mg; 50 mg - sertraline
cordarone
sanofi winthrop industrie - amjodarono hidrochloridas - tabletės - 50 mg/ml; 200 mg - amiodarone
propofol fresenius
fresenius kabi deutschland gmbh - propofolis - injekcinė ar infuzinė emulsija - 10 mg/ml; 20 mg/ml - propofol
sertraline-teva
teva pharma b.v. - sertralinas - plėvele dengtos tabletės - 50 mg - sertraline
baclosal
zakłady farmaceutyczne polpharma s.a. - baklofenas - tabletės - 10 mg; 25 mg - baclofen
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antinavikiniai vaistai - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.